Winfried Koch

410 total citations
16 papers, 295 citations indexed

About

Winfried Koch is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Winfried Koch has authored 16 papers receiving a total of 295 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 5 papers in Molecular Biology and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Winfried Koch's work include HER2/EGFR in Cancer Research (4 papers), Monoclonal and Polyclonal Antibodies Research (3 papers) and Computational Drug Discovery Methods (2 papers). Winfried Koch is often cited by papers focused on HER2/EGFR in Cancer Research (4 papers), Monoclonal and Polyclonal Antibodies Research (3 papers) and Computational Drug Discovery Methods (2 papers). Winfried Koch collaborates with scholars based in Germany, United States and Italy. Winfried Koch's co-authors include Armin Schneider, Rico Laage, Gerhard Vogt, James Mandell, Eleanor C. McFarland, Glenn M. Preminger, Günter Auerbach, Rainer Kollmar, Michael Rosenkranz and Roland Veltkamp and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Stroke.

In The Last Decade

Winfried Koch

15 papers receiving 284 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Winfried Koch Germany	9	70	61	61	50	41	16	295
Kyoichi Nomura Japan	12	86 1.2×	42 0.7×	55 0.9×	48 1.0×	50 1.2×	34	700
Stefan Reischl Germany	11	131 1.9×	50 0.8×	80 1.3×	71 1.4×	34 0.8×	27	412
Sravanthi Koduri United States	11	131 1.9×	64 1.0×	39 0.6×	28 0.6×	66 1.6×	37	425
Caroline Gahm Sweden	10	113 1.6×	39 0.6×	26 0.4×	59 1.2×	53 1.3×	17	407
Bingzhen Cao China	11	134 1.9×	38 0.6×	43 0.7×	24 0.5×	40 1.0×	26	387
Xiaolei Shi China	10	69 1.0×	54 0.9×	39 0.6×	54 1.1×	122 3.0×	28	504
Walter Rinner Austria	10	65 0.9×	49 0.8×	112 1.8×	42 0.8×	39 1.0×	14	384
Jean‐Luc Carré France	11	82 1.2×	18 0.3×	35 0.6×	39 0.8×	26 0.6×	24	349
Gaetano Desina Italy	8	213 3.0×	29 0.5×	48 0.8×	48 1.0×	26 0.6×	10	502

Countries citing papers authored by Winfried Koch

Since Specialization

Citations

This map shows the geographic impact of Winfried Koch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Winfried Koch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Winfried Koch more than expected).

Fields of papers citing papers by Winfried Koch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Winfried Koch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Winfried Koch. The network helps show where Winfried Koch may publish in the future.

Co-authorship network of co-authors of Winfried Koch

This figure shows the co-authorship network connecting the top 25 collaborators of Winfried Koch. A scholar is included among the top collaborators of Winfried Koch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Winfried Koch. Winfried Koch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Rohde, Gernot, Stephan Stenglein, Hans Prozesky, et al.. (2023). Efficacy and safety of zapnometinib in hospitalised adult patients with COVID-19 (RESPIRE): a randomised, double-blind, placebo-controlled, multicentre, proof-of-concept, phase 2 trial. EClinicalMedicine. 65. 102237–102237. 11 indexed citations

Gaiser, Maria Rita, Sylvie Lorenzen, Kirsten Merx, et al.. (2019). Evaluation of EGFR inhibitor‐mediated acneiform skin toxicity within the double‐blind randomized EVITA trial: A thorough gender‐specific analysis using the WoMo score. Cancer Medicine. 8(9). 4169–4175. 4 indexed citations

Rüschoff, Josef, Annette Lebeau, Hans‐Peter Sinn, et al.. (2019). Statistical modelling of HER2-positivity in breast cancer: Final analyses from two large, multicentre, non-interventional studies in Germany. The Breast. 49. 246–253. 1 indexed citations

Baretton, Gustavo, Hans Kreipe, Peter Schirmacher, et al.. (2019). HER2 testing in gastric cancer diagnosis: insights on variables influencing HER2-positivity from a large, multicenter, observational study in Germany. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 474(5). 551–560. 17 indexed citations

Ophoven, Arndt van, et al.. (2019). Efficacy of pentosan polysulfate for the treatment of interstitial cystitis/bladder pain syndrome: results of a systematic review of randomized controlled trials. Current Medical Research and Opinion. 35(9). 1495–1503. 32 indexed citations

Hartmann, Arndt, Peter Schirmacher, William Sterlacci, et al.. (2018). BRAF mutation testing in melanoma: results from a German observational multicenter study. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 474(1). 71–78.

Gaiser, Maria Rita, Alexander Skorokhod, Benjamin Weide, et al.. (2017). Variables that influence BRAF mutation probability: A next-generation sequencing, non-interventional investigation of BRAFV600 mutation status in melanoma. PLoS ONE. 12(11). e0188602–e0188602. 5 indexed citations

Baretton, Gustavo, Hans Kreipe, Peter Schirmacher, et al.. (2017). HER2 testing in gastric cancer diagnosis: Insights on variables influencing HER2-positivity from a large, multicenter, observational study in Germany.. Journal of Clinical Oncology. 35(4_suppl). 15–15. 5 indexed citations

Rüschoff, Josef, Annette Lebeau, Hans Kreipe, et al.. (2016). Assessing HER2 testing quality in breast cancer: variables that influence HER2 positivity rate from a large, multicenter, observational study in Germany. Modern Pathology. 30(2). 217–226. 28 indexed citations

10.

Rüschoff, Josef, Annette Lebeau, Hans Kreipe, et al.. (2015). Assessing HER2 testing quality in breast cancer (BC): Variables that influence HER2-positivity from a large, multicenter, observational study in Germany.. Journal of Clinical Oncology. 33(15_suppl). 11062–11062. 1 indexed citations

11.

Bilo, Grzegorz, Winfried Koch, Satoshi Hoshide, & Gianfranco Parati. (2014). Efficacy of olmesartan/amlodipine combination therapy in reducing ambulatory blood pressure in moderate-to-severe hypertensive patients not controlled by amlodipine alone. Hypertension Research. 37(9). 836–844. 12 indexed citations

12.

Giannitsis, Evangelos, Eberhard Spanuth, Marcus E. Kleber, et al.. (2013). High-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide predict mortality in stable coronary artery disease: results from the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Clinical Chemistry and Laboratory Medicine (CCLM). 51(10). 2019–2028. 17 indexed citations

13.

Flöel, Agnes, Tobias Warnecke, Thomas Duning, et al.. (2011). Granulocyte-Colony Stimulating Factor (G-CSF) in Stroke Patients with Concomitant Vascular Disease—A Randomized Controlled Trial. PLoS ONE. 6(5). e19767–e19767. 32 indexed citations

14.

Schäbitz, Wolf R., Rico Laage, Gerhard Vogt, et al.. (2010). AXIS. Stroke. 41(11). 2545–2551. 91 indexed citations

15.

Kraemer, Klaus, Winfried Koch, & P. P. Hoppe. (2004). Is All‐Rac‐α‐Tocopherol Different from RRR‐α‐Tocopherol Regarding Cardiovascular Efficacy?: A Meta‐Analysis of Clinical Trials. Annals of the New York Academy of Sciences. 1031(1). 435–438. 6 indexed citations

16.

Mandell, James, et al.. (1983). Congenital polycystic kidney disease. Genetically transmitted infantile polycystic kidney disease in C57BL/6J mice.. PubMed. 113(1). 112–4. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact